Recurrent gene rearrangements involving the androgen-regulated transmembrane protease serine 2 (TMPRSS2) and ETS transcription factor, v-ets erythroblastosis virus E26 oncogene homolog (ERG) occur in ~50% of prostate cancer (PCa) patients1. Here, ERG is linked to posterior cortical atrophy.